ReviewImmunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: A systematic review and implications for polio eradication
Introduction
The prevalence of poliomyelitis has decreased dramatically since the 1960s with the development and widespread use of the live attenuated Sabin oral poliovirus vaccine (OPV). OPV became the backbone of worldwide vaccine strategies launched by the Global Polio Eradication Initiative (GPEI) due to its low cost, ability to induce mucosal immunity, and ease of administration [1], [2]. However, the potential for OPV to mutate into neurovirulent strains through prolonged intestinal replication—which can result in vaccine-derived poliovirus (VDPV) outbreaks—poses a challenge to global polio eradication [3], [4], [5]. Given their relation to key polio endgame issues such as OPV cessation and vaccine stockpile design, VDPVs thus have implications for vaccination policies worldwide [6], [7]. Numerous studies have been conducted to assess the risks, costs, and benefits of different eradication options, including the evaluation of scenarios with VDPVs [8], [9], [10], [11].
VDPVs are identified based on their degree of genetic divergence from the parent OPV strain and can be comparable to wild-type poliovirus in their capacity to cause paralysis [12]. By definition, VDPVs of serotypes 1 and 3 have >1% genetic divergence, whereas VDPVs of serotype 2 have >0.6% divergence from parent OPV strains [12]. VDPVs are classified into 3 categories: cVDPVs, aVDPVs, and iVDPVs. Circulating vaccine-derived polioviruses (cVDPVs) occur when VDPVs establish and sustain circulation in under-immunized communities for an extended period of time [9], [13], [14], [15], [16]. Ambiguous vaccine-derived polioviruses (aVDPVs) are either isolated from people with no known immunodeficiency or from sewage whose ultimate source is unknown [16], [17], [18]. Immunodeficiency-related vaccine-derived polioviruses (iVDPVs) are a special case of VDPVs in which patients have a primary immunodeficiency (PID) [16], [19]. Unlike immunocompetent persons, who excrete the vaccine virus for a limited period of time, some immunodeficient persons are unable to clear intestinal replication of the vaccine virus after exposure to OPV [19], [20]. In this regard, iVDPVs pose a significant threat to the eradication campaign, as individuals that harbor the vaccine virus for prolonged periods of time could serve as sources of poliovirus reintroduction after polio eradication [16], [21], [22].
Several key efforts have been made to achieve better assessment of the risks posed by iVDPVs in recent years. The GPEI maintains a registry of iVDPV cases. Although this registry is not publicly available, a list of these cases is periodically published in the World Epidemiological Record (WER) and Morbidity and Mortality Weekly Report (MMWR) [12], [23], [24], [25], [26], [27], [28], [29], [30], [31]. Additional studies have been launched to search for potential iVDPV carriers. Although these studies either identified no or few cases, they are an important step toward understanding the true risk and prevalence of iVDPVs, as well as in confirming the feasibility and value of conducting polio surveillance programs [32], [33], [34], [35], [36].
A review by Kew et al. [19] providing a comprehensive overview of VDPVs included a brief chapter summarizing the main features of iVDPVs and a list of documented iVDPV excretors from 1962 to 2003. A review by Tebbens et al. [21] investigating the risks of continued vaccination with OPV modeled the occurrence of paralysis due to infection with the vaccine virus by type of VDPV. A list of iVDPV cases reported in 1962–2005 was presented, which the authors drew upon for inputs to their model. They also stratified their analysis by income level of the country in which a case was reported to assess regional differences. A review by Van de Ven et al. [37] explored the role of prolonged gastrointestinal infections in causing inflammatory enteropathy in patients with a PID. Poliovirus was among the enteroviruses examined, and the authors identified a select number of cases that were iVDPVs, with the most recent case reported in 2005.
In light of the initiatives launched by the GPEI and other researchers, as well as prior reviews regarding iVDPVs, we present the results of a systematic review of reported iVDPV cases in the literature from 1962 to 2012. The aims of this study are two-fold. The first is to present general characteristics and significant trends observed amongst iVDPV cases over five decades, elucidating key findings that have implications for polio eradication such as patterns in poliovirus genome evolution, regional differences in case prevalence, and information regarding case detection and transmission. Over 30 iVDPV cases have been reported since 2006, and given the increasing attention paid to iVDPVs as the world approaches polio eradication, our review provides an update on confirmed iVDPV cases published in the scientific literature.
Second, we aim to foster greater interest and further research regarding iVDPVs that will be useful in the development of appropriate vaccination strategies and policies to achieve and maintain polio eradication. To date, there are no licensed antiviral compounds for poliovirus. There are several antiviral agents such as pirodavir and pleconaril that are known to inhibit poliovirus replication and hence chronic excretion, but data have shown that pleconaril lacks efficacy against certain serotypes of poliovirus [38]. Thus far, the Polio Antivirals Initiative (PAI) has reported pocapavir as a promising agent [39], [40], [41].
Section snippets
Search strategy
Published citations of iVDPV cases from January 1960 to November 2012 were obtained using search strings developed for PubMed, Science Direct, Scopus, and Web of Science, respectively. Key words used to identify citations containing iVDPV cases included immunodeficiency, immunocompromised, immunosuppressed, polio, poliomyelitis, “vaccine derived polioviruses”, VDPV, iVDPV, “oral poliovirus vaccine”, OPV, “acute flaccid paralysis”, AFP, “vaccine associated paralytic poliomyelitis”, recombinant,
Prevalence and location of iVDPV cases
68 iVDPV cases from 49 manuscripts published between January 1960 and November 2012 met our inclusion criteria. We excluded eight manuscripts that described immunodeficient persons shedding poliovirus but did not report sequencing data to confirm that this shed virus was a VDPV [47], [48], [49], [50], [51], [52], [53], [54]. None of the cases reported in these manuscripts was ever reported in a WER/MMWR. Most of these manuscripts were published before the onset of routine OPV sequencing.
Fig. 2
Discussion
This study is a comprehensive update of confirmed iVDPV cases published in the scientific literature from 1962 to 2012. We found that the majority of reported iVDPV cases had underlying antibody deficiencies, presented with AFP, and died with an overall mortality rate of 62%. We identified a poliovirus genome VP1 mutation rate of 0.72% per year through regression analysis, as well as a higher median percent divergence for iVDPV1 cases. This mutation rate, which approaches the estimated
Conclusion
This study is a comprehensive update of confirmed iVDPV cases published in the scientific literature spanning five decades. It describes clinically relevant trends in reported iVDPV cases worldwide and also highlights the regional and economic disparities of reported iVDPV cases. These results may be informative in designing policy in the post-eradication era, given the relevance of iVDPV cases to polio endgame issues such as OPV cessation and ecologic poliovirus surveillance.
Conflict of interest
Authors do not have any conflict of interest.
Author contributions
J.G. and S.B.W. equally contributed to the literature search, study extraction, data analysis, drafts, and revisions of the manuscript. N.S., M.H. and Y.M. participated in the study design. M.H. and N.S. participated in the initial screening process, supervised the methodologies of the project and extensively reviewed drafts of the manuscript. Y.M. critically reviewed versions of the manuscript.
Acknowledgements
We would like to give thanks to Meira F. Halpern and Stacy Huang for their feedback on the manuscript, and the librarians at Stanford University and University of Central Florida for their statistical and technical support.
References (77)
- et al.
A vision of a world without polio: the OPV cessation strategy
Biologicals
(2006) - et al.
Optimal vaccine stockpile design for an eradicated disease: application to polio
Vaccine
(2010) Vaccine-derived poliovirus from long term excretors and the end game of polio eradication
Biologicals
(2006)Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication
Vaccine
(2009)- et al.
Search for poliovirus long-term excretors among patients affected by agammaglobulinemia
Clin Immunol
(2004) - et al.
The feasibility of identifying children with primary immunodeficiency disorders: preparation for the polio post-eradication era in Bangladesh
Vaccine
(2012) - et al.
Prevalence of prolonged and chronic poliovirus excretion among persons with primary immune deficiency disorders in Sri Lanka
Vaccine
(2012) - et al.
Surveillance of suspected poliomyelitis in Albania, 1980–1995: suggestion of increased risk of vaccine associated poliomyelitis
Vaccine
(1998) - et al.
Vaccine-related paralytic poliomyelitis in an immunodeficient child
J Pediatr
(1971) - et al.
Nonparalytic poliovirus infections in patients with severe combined immunodeficiency disease
J Pediatr
(1974)
Combined immunodeficiency and vaccine-related poliomyelitis in a child with cartilage-hair hypoplasia
J Pediatr
Vaccine-associated poliomyelitis in a child with sex-linked agammaglobulinemia
J Pediatr
Neurologic complications in oral polio vaccine recipients
J Pediatr
Reaching the last one per cent: progress and challenges in global polio eradication
Curr Opin Virol
Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants
J Pediatr
Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States
Pediatr Clin North Am
OPV vs IPV: past and future choice of vaccine in the global polio eradication program
Partn Health Reform Proj
The polio endgame
N Engl J Med
Eradication of poliovirus: fighting fire with fire
J Infect Dis
Polio eradication: current status and challenges
J Family Med Prim Care
National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication
Expert Rev Vaccines
Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses
Risk Anal
Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs)
Risk Anal
Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation
Expert Rev Vaccines
The risks, costs, and benefits of possible future global policies for managing polioviruses
Am J Public Health
Update on vaccine-derived polioviruses detected worldwide, April 2011–June 2012
Wkly Epidemiol Rec
Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus
Science
Circulation of a type 2 vaccine-derived poliovirus – Egypt, 1982–1993
MMWR Morb Mortal Wkly Rep
Public health dispatch: poliomyelitis—Madagascar, 2002
MMWR Morb Mortal Wkly Rep
Global Polio Eradication Initiative
Vaccine-derived polioviruses and the endgame strategy for global polio eradication
Annu Rev Microbiol
Emerging/disappearing viruses future issues concerning polio eradication
Virus Res
Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication
Risk Anal
Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis
Expert Rev Vaccines
Prolonged poliovirus excretion in an immunodeficient person with vaccine-associated paralytic poliomyelitis
MMWR Morb Mortal Wkly Rep
Poliovirus infections in four unvaccinated children – Minnesota, August–October 2005
MMWR Morb Mortal Wkly Rep
Update on vaccine-derived polioviruses
MMWR Morb Mortal Wkly Rep
Update on vaccine-derived polioviruses – worldwide, January 2006–August 2007
MMWR Morb Mortal Wkly Rep
Cited by (46)
Isolation and characterization of a Sabin 3/Sabin 1 recombinant vaccine-derived poliovirus from a child with severe combined immunodeficiency
2022, Virus ResearchCitation Excerpt :The patient had first taken 1 dose of bOPV one year before on Jan, 2018. Therefore, the rate of sequence evolution was estimated at 1.4% nucleotide substitutions/year based on the percentage of changes in the last isolate 301-5, which was similar with previously reported iVDPVs (Guo et al., 2015). Mutations were identified in residues known to be involved in receptor interactions of poliovirus with host cells, which may contribute to attenuation and temperature sensitivity.
Vaccines in Patients with Primary Immune Deficiency
2020, Immunology and Allergy Clinics of North AmericaCitation Excerpt :The vaccine strain polio virus can persist and be excreted for years to cause disease in unimmunized contacts. Such reported cases are rare (approximately 1.3 cases per year total from 26 countries surveyed in one study59), but this may underestimate the actual number of cases of transmission.64 Rotavirus vaccine is a combination of elements from human and bovine strains.
Seroprevalence of antibodies against the three serotypes of poliovirus and IPV vaccine response in adult solid organ transplant candidates
2018, VaccineCitation Excerpt :In most cases of immunodeficiency-related vaccine-derived poliovirus (iVDPV), the immunodeficiency has been diagnosed only after the development of paralysis [12]. In addition, approximately 7% of iVDPV cases were infected by vaccinated contacts [13]. This reinforces the need to identify susceptible individuals, especially in groups of immunodeficient patients in regions where the oral vaccine is still used.
Update: Vaccines in primary immunodeficiency
2018, Journal of Allergy and Clinical ImmunologyCitation Excerpt :Vaccine-derived polioviruses can persist in patients with PIDs, undergo genetic drift, and be excreted (sometimes for years) to cause outbreaks of clinically significant (often fatal) disease in areas where vaccine coverage is low. Detected or reported immunodeficiency-associated cases are relatively rare (68 cases in 26 countries in 52 years),79 but prolonged excretion of poliovirus in a small proportion of subjects is sufficient to seriously hamper attempts toward global eradication. The human/bovine reassortant pentavalent rotavirus vaccine has been in routine use for only a decade.